| Actual |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Real Estate > Investing > Purchase Agreement for Mexican Real Estate |
|
Actual - Purchase Agreement for Mexican Real Estate
The Purchase Agreement or Contract to Purchase is one of
the most important documents in a real estate tr According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ansaction.
The Purchase Agreement is generally defined as a contract
for the purchase and sale of real e ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in tate between a Buyer and
Seller in which the seller agrees to sell and the buyer agrees
to buy under cer lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ain specific terms and conditions. In
Mexico this contract will contain the following clauses and provisi here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ns: 1) Clearly states that this is a Purchase Agreement by means of a trust (fidecomiso). 2) Clearly de d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ines the buyer and seller. 2a)If either buyer or seller is other than an individual then the company(ies ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc must be spelled out clearly in terms of legal
company names and who are the legal representatives. 2b)T easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi e seller is designated the "PROMISSOR SELLER"
and the buyer is designated the "PROMISSOR
PURCHASER", "EL nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically PROMITENTE VENDEDOR" y "EL
PROMITENTE COMPRADOR". 3) A complete identification of the real estate in thi and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
transaction showing the recording of the deed granting the
property to the seller. 4) A legal surveyer ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi description of the property
including the cadastral code and size of house and lot. 5) Transfer of code ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a s related to the "fraccionamiento"
in which this property is located and recognition by
buyer of the exi dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod tence of any neighborhood governing
associations. 6) The current legal description of the property (com cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin lete street address). 7) Clearly stated purchase price in US Dollars. 8) The down payment in US Dollars. tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen 9) The balance to be paid by buyer to seller upon completion of the trust (fidecomiso) process. 10)A cl t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ar demarcation of fees and responsible party
for paying those fees in conjunction with this transaction.
ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust (See section on Costs Associated with a Real Estate
Purchase.) 11)Clear annunciation of penalties associ y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ted with
failure of buyer or seller to complete this transaction. 12)Obligation of seller to transfer pr . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de perty free of liens
and with all bills related to property paid for before
approval of trust. For more elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Effective Sales Letter Writing - 7 Tips to Make Killer Sales Letters Chitika Eminimalls - Look Before You Leap - The Pros and Cons For Webmasters Finding the Best Credit Card for You and Your Lifestyle
|